MedTrace Logo

Reduction of Polypharmacy in Elderly People With Multiple Diseases

NCT05526963 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1146

Last updated 2025-01-09

No results posted yet for this study

Summary

Elderly GP patients are often treated with five or more medications and therefore prone to adverse drug reactions (ADR). Potentially inappropriate prescriptions (PIPs) lead to increased adverse events like falls, hospitalizations and mortality. The primary aim of this study to reduce the frequency of ADRs in multimorbid patients aged 70 years and older by reducing polypharmacy.

Conditions

  • Polypharmacy
  • Multimorbidity

Interventions

OTHER

Medication plan review

Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.

BEHAVIORAL

Adherence support

Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.

Sponsors & Collaborators

  • University of Leipzig

    collaborator OTHER

  • Hannover Medical School

    collaborator OTHER

  • Martin-Luther-Universität Halle-Wittenberg

    lead OTHER

Principal Investigators

  • Thomas Frese, Prof. · MLU Halle-Wittenberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2025-10-30
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05526963 on ClinicalTrials.gov